Cavatak: Completed Phase II enrollment

Viralytics completed enrollment of 54 stage IIIC/IV malignant melanoma patients in the 2-stage, open-label, U.S. Phase II CALM trial evaluating 10 intratumoral injections of Cavatak over 18 weeks. Las...